Skip to main content
TipRanks
Go Ultimate75% OFF

NEUCA S.A. (0MJR) AI Stock Analysis

0 Followers
GB:0MJR

NEUCA S.A.

(LSE:0MJR)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Stable MarginsStable margins indicate effective cost management and pricing strategies, supporting NEUCA's profitability and operational efficiency over time.
Negative Factors
Earnings GrowthNegative EPS growth reflects challenges in maintaining earnings momentum, which could impact NEUCA's ability to reinvest in its business and sustain shareholder returns.

NEUCA S.A. (0MJR) vs. iShares MSCI United Kingdom ETF (EWC)

-5%0%5%10%15%20%25%30%GB:0MJR0.00%EWC+17.53%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
PLN 3.25B
Dividend Yield
2.56%
Average Volume (3M)
―
Price to Earnings (P/E)
16.4
Beta (1Y)
―
Revenue Growth
8.42%
EPS Growth
43.47%
Country
UK
Employees
5,004
Sector
Healthcare
Sector Strength
51
Industry
Medical - Distribution

NEUCA S.A. Business Overview & Revenue Model

Company Description

NEUCA S.A., headquartered in Torun, Poland, specializes in supplying pharmaceutical products to pharmacies and healthcare facilities throughout the country. The firm structures its business around distinct segments: wholesale pharmaceutical distribut...

NEUCA S.A. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

GB:0MJR against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
PL:BIOPL:BIO45NeutralPLN 297.09M-25.18-1.97%―-15.67%-307.60%
PL:CLNPL:CLN42NeutralPLN 830.24M7.3324.89%―――
PL:MABPL:MAB41NeutralPLN 151.76M-2.68-124.37%―11.57%4.35%

* Healthcare Sector Average

Performance Comparison

-20%0%20%40%GB:0MJRPL:SVEPL:CLNPL:BIOPL:MRCPL:MABDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
GB:0MJR and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
GB:0MJRNEUCA S.A.760.000.000.00%
PL:SVEBiomed-Lublin Wytwornia Surowic i Szczepionek S.A.2.68-1.35-33.42%
PL:CLNCelon Pharma SA15.40-6.10-28.37%
PL:BIOBIOTON S.A.3.46-0.53-13.28%
PL:MRCMercator Medical SA56.5018.0546.96%
PL:MABMabion SA9.391.7222.43%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.